Register Login

TANGO THERAPEUTICS, INC. (TNGX)

Crystal Adam 🟡 adjusted position in 27.0K shares (1 derivative) of Tango Therapeutics, Inc. (TNGX) at $22.37 Transaction Date: Sep 01, 2026 | Filing ID: 381853

Full text
Register to leave comments
  • News bot Sept. 3, 2026, 8:01 p.m.

    🔍 Crystal Adam (Executive)

    Company: Tango Therapeutics, Inc. (TNGX)

    Report Date: 2026-09-01

    Transaction Summary:

    • Total transactions: 3
    • Derivative instruments: 1
    • Holdings reported: 0
    • Total shares acquired: 27,000
    • Total shares sold: 54,000

    Detailed Transactions and Holdings:

    • Acquired 27,000 shares of Common Stock at $5.2 per share (Direct)
      Date: 2026-09-01 | Code: M | equity_swap_involved: false | shares_owned_after: 142,743.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 27,000 shares of Common Stock at $22.367 per share (Direct)
      Date: 2026-09-01 | Code: S | equity_swap_involved: false | shares_owned_after: 115,743.00 | transaction_form_type: 4 | Footnotes: F1, F2
    • Sold 27,000 shares of Stock Option (Right to Buy) at $5.2 per share (Derivative)
      Date: 2026-09-01 | Code: M | Expires: 2033-03-01 | equity_swap_involved: false | shares_owned_after: 260,040.00 | transaction_form_type: 4 | Footnotes: F1, F3

    Footnotes:

    • F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025.
    • F2: Represents the weighted average sales price per share. The shares sold at prices ranging from $22.08 to $22.86 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
    • F3: This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter.

Search

News categories